Filing Details
- Accession Number:
- 0001610717-25-000030
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-02-20 17:14:01
- Reporting Period:
- 2025-02-18
- Filing Date:
- 2025-02-20
- Accepted Time:
- 2025-02-20 17:14:01
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1885522 | Neumora Therapeutics Inc. | NMRA | Biological Products, (No Disgnostic Substances) (2836) | 844367680 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1993953 | Lee Michael Milligan | C/O Neumora Therapeutics, Inc. 490 Arsenal Way, Suite 200 Watertown MA 02472 | See Remarks | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2025-02-18 | 1,978 | $1.69 | 22,470 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on August 30, 2024, which provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered restricted stock unit in an amount necessary to satisfy the applicable withholding obligation.
- This transaction was executed in multiple trades in prices ranging from $1.6937 to $1.695, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.